Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases.
The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.
Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 13, 24 | -0.16 Increased by +75.38% | -0.10 Decreased by -60.00% |
| May 7, 24 | -0.25 Increased by +58.33% | -0.44 Increased by +43.18% |
| Mar 28, 24 | -0.71 Decreased by -26.79% | -0.58 Decreased by -22.41% |
| Nov 13, 23 | -0.57 Decreased by -7.55% | -0.57 |
| Aug 10, 23 | -0.65 Decreased by -30.00% | -0.52 Decreased by -25.00% |
| May 11, 23 | -0.60 Decreased by -13.21% | -0.60 |
| Mar 27, 23 | -0.56 Decreased by -30.23% | -0.60 Increased by +6.67% |
| Nov 8, 22 | -0.53 Decreased by -1.92% | -0.57 Increased by +7.02% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 0.00 Decreased by N/A% | -5.36 M Increased by +72.55% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 734.00 K Increased by +N/A% | -8.43 M Increased by +40.20% | Decreased by -1.15 K% Decreased by N/A% |
| Dec 31, 23 | 734.00 K Increased by +N/A% | -23.55 M Decreased by -86.37% | Decreased by -3.21 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -19.20 M Decreased by -57.68% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -19.53 M Decreased by -60.18% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -14.09 M Decreased by -7.92% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -12.64 M Decreased by -19.15% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -12.17 M Increased by +4.41% | Decreased by N/A% Decreased by N/A% |